文献速递中枢神经肿瘤放疗放疗物理与技术

肿瘤电场治疗换能器阵列对胶质母细胞瘤放疗计划剂量学影响

Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study.
PubMed 文献 · Radiat Oncol · 2018-02-23

该计划研究在体模中比较MV-CT与kV-CT计划剂量和实测剂量,发现TTField阵列所致衰减实测为2.7%–3.7%,与MV-CT计算一致而与kV-CT计算不符。基于MV-CT的VMAT计划适形性和均匀性不受阵列影响,OAR剂量变化小于0.5 Gy,提示无需每日更换阵列,但同步治疗应在临床试验内进行。

要点

  • TTField阵列在2、3、4 cm深度实测衰减分别为3.4%、3.7%、2.7%,与MV-CT计算一致。
  • MV-CT引导的VMAT计划适形性和均匀性不受TTField阵列影响。
  • OAR剂量变化小于0.5 Gy,颅底附近病例需注意;同步治疗应在临床试验内进行。

核心结论

  • 基于MV-CT的剂量计算在存在TTField阵列时仍可获得可靠剂量分布。
  • TTField阵列与VMAT剂量投照之间的相互作用很小且临床不相关。
  • 就深部OAR而言,无需每日更换TTField阵列。
  • 当VMAT计划在无阵列的计划CT上优化时,放疗可行。
  • 由于同步治疗对OAR的生物学效应未知,同步治疗应仅在临床试验内进行。

研究设计与样本

  • 计划研究,在RW3平板体模中比较基于MV-CT和kV-CT的计划剂量与实测剂量。
  • 在Alderson头体模的无TTField阵列MV-CT上优化VMAT计划,再在配备TTField阵列的同一体模上重新计算。
  • 比较OAR和PTV的剂量。

主要发现

  • RW3平板体模2、3、4 cm深度处TTField阵列所致衰减实测分别为3.4%、3.7%、2.7%。
  • 基于MV-CT计算的衰减分别为1.2%、2.5%、2.5%,与实测一致。
  • 基于kV-CT计算的衰减分别为7.1%、8.2%、8.6%,与实测不一致。
  • 基于MV-CT的VMAT计划再计算显示适形性和均匀性不受TTField阵列存在的影响。
  • OAR剂量可增加或减少小于0.5 Gy,颅底附近病例应予以考虑。

关键数值与推荐

  • RW3平板体模2、3、4 cm深度实测衰减分别为3.4%、3.7%、2.7%。
  • MV-CT计算衰减分别为1.2%、2.5%、2.5%;kV-CT计算衰减分别为7.1%、8.2%、8.6%。
  • OAR剂量变化小于0.5 Gy。

临床怎么用

  • 采用基于MV-CT的剂量计算以评估TTField阵列存在时的剂量分布。
  • VMAT计划可在无阵列的计划CT上优化。
  • 深部OAR无需因TTField阵列而每日更换阵列。
  • 颅底附近病例需注意OAR剂量小于0.5 Gy的变化。
  • 同步TTField与放疗应在临床试验内进行。

局限性

  • 研究为体模计划研究,非患者体内验证。
  • 同步治疗对OAR的生物学效应目前未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor-Treating Fields (TTFields) are a novel treatment strategy for glioblastoma (GBM) that is approved for the use concomitantly to adjuvant chemotherapy. Preclinical data suggest a synergistic interaction of TTFields and radiotherapy (RT). However, the dosimetric uncertainties caused by the highly dense arrays have led to caution of applying the TTF setup during RT. METHODS: In a RW3 slab phantom we compared the MV- and kV-CT based planned dose with the measured dose. VMAT-plans were optimized on MV-CTs of an Alderson head phantom without TTF arrays and then re-calculated on the same phantom equipped with TTF arrays. Dose at organs at risk (OAR) and target volumes (PTVs) were compared. RESULTS: Measurements at a depth of 2, 3 and 4 cm of a RW 3 slab phantom show an attenuation due to TTField arrays of 3.4, 3.7 and 2.7% respectively. This was in-line with calculated attenuations based on MV-CT (1.2, 2.5 and 2.5%) but not with the attenuation expected from kV-CT based calculations (7.1, 8.2 and 8.6%). Consecutive MV-CT based VMAT planning and re-calculation reveals, that the conformity and homogeneity are not affected by the presence of TTField arrays. The dose at organs at risk (OAR) can show increases or decreases by < 0.5 Gy, which should be considered especially in cases next to the scull base. CONCLUSION: MV-CT based dose calculation results in reliable dose distributions also in the presence of TTField arrays. There is a small but clinically not relevant interaction between the TTField arrays and VMAT dose application. Thus, daily replacement of TTField arrays is not necessary in regard to deeply located OARs. RT is feasible, when a VMAT treatment plan is optimized to an array free planning CT. As the biologic effect of a concomitant treatment especially on OARs is currently unknown, a concomitant treatment should be performed only within clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Straube C, Oechsner M, Kampfer S, et al. Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study. Radiat Oncol. 2018. PMID: 29471879. doi:10.1186/s13014-018-0976-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。